| At a glance | Obstruction to LV outflow; classic SAD triad (Syncope, Angina, Dyspnea) signals need for AVR. | Genetic LVH (often asymmetric septal) with dynamic LVOT obstruction — leading cause of SCD in young athletes. |
|---|
| Classic presentation | Crescendo-decrescendo systolic ejection murmur at RUSB radiating to carotids, pulsus parvus et tardus, late-peaking murmur in severe disease.; Classic SAD triad (onset of any symptom marks severe AS and dramatically worsens prognosis):; • Syncope — exertional; from inability to augment CO across fixed obstruction; • Angina — from… | Often asymptomatic; HCM detected on screening or after sudden death of a family member; Exertional dyspnea, fatigue (most common symptom); Anginal chest pain; Palpitations, presyncope, syncope (especially exertional — ominous); Sudden cardiac death may be the first manifestation; Brisk, bisferiens carotid pulse (spike-and-dome);… |
|---|
| Workup / key labs | Standard CV labs: lipid panel, A1c, BMP, BNP; Pre-operative workup if AVR planned | Adult: maximum LV wall thickness ≥15 mm unexplained by loading conditions, or ≥13 mm with affected family member or positive genetic testing. Obstructive HCM = peak LVOT gradient ≥30 mmHg at rest or with provocation (Valsalva, standing, exercise); ≥50 mmHg is hemodynamically significant and is the threshold for septal reduction therapy… |
|---|
| Imaging | ECG: LVH with strain (left precordial T-wave inversions), left atrial enlargement, occasionally LBBB or AV block from septal calcification; CXR: cardiomegaly late; aortic root calcification visible on lateral; Transthoracic echocardiogram (KEY DIAGNOSTIC TEST):; • Mild: AVA >1.5 cm², mean gradient <20 mmHg, peak velocity <3 m/s; •… | Transthoracic echo — diagnostic; document septal thickness, LVOT gradient at rest and with provocation (Valsalva, exercise), SAM, MR; Cardiac MRI with late gadolinium enhancement — extent of fibrosis and SCD risk stratification, mass quantification, apical HCM identification; ECG — LVH with strain, deep narrow Q waves (septal… |
|---|
| First-line treatment | Asymptomatic AS — no proven benefit from medical therapy to slow progression; Treat concomitant HTN per standard guideline-directed therapy (ACEi/ARB acceptable), starting at a low dose and titrating slowly with close BP monitoring (Class 1); avoid abrupt preload reduction such as nitrates in severe AS; Lipid-lowering therapy does NOT… | Avoid dehydration, excess alcohol, and sudden standing; mild-to-moderate exercise is encouraged, and vigorous or competitive sports are decided by shared decision-making with an HCM expert rather than blanket disqualification (2024 AHA/ACC); Symptomatic obstructive HCM: non-vasodilating beta-blocker (metoprolol, atenolol, propranolol)… |
|---|